The CONTROL Study

  • Research type

    Research Study

  • Full title

    The effect of Canagliflozin 300mg, in subjects without diabetes after bariatric surgery, on glucose homeostasis (The CONTROL Study): A proof-of-concept, randomised, open-label, two period crossover study.

  • IRAS ID

    263968

  • Contact name

    Dimitris Papamargaritis

  • Contact email

    dimitris.papamargaritis@uhl-tr.nhs.uk

  • Sponsor organisation

    University of Leicester

  • Eudract number

    2019-004041-32

  • Duration of Study in the UK

    1 years, 3 months, 31 days

  • Research summary

    Symptoms due to low sugar levels (hypoglycaemia)a few hours after eating is a common problem after weight loss surgery which can be distressing. Currently there is no good treatment available for this problem. The underlying cause is unclear, however after weight-loss surgery, people with low glucose levels (hypoglycaemia) after a meal produce more than the necessary amount of insulin.

    Canagliflozin, a treatment for type 2 diabetes, has been shown to reduce the insulin production after a meal in patients without diabetes. Moreover, in patients without diabetes, the lowest glucose levels 2-3 hours after eating are slightly higher with the use of canagliflozin. If this is also the case after weight-loss surgery, then canagliflozin could be a treatment option for hypoglycaemia after eating due to weight-loss surgery. The objective of this study is to investigate the effect of canagliflozin on glucose, insulin and hormones secreted from the gut in people without diabetes after weight-loss surgery.

    Participants will be provided with canagliflozin tablets for 5 days or no treatment. At the 5th day, participants from both groups will drink a milkshake and we will investigate their glucose, insulin and hormonal levels. After 3 weeks without any treatment, participants will receive again for 5 days either canagliflozin or no treatment (opposite to what they received initially) and will undergo another milkshake test. Participants will also wear a glucose monitoring device for the period receiving canagliflozin tablets and the period without treatment which will assess their glucose levels in everyday life.

  • REC name

    Yorkshire & The Humber - Leeds West Research Ethics Committee

  • REC reference

    20/YH/0123

  • Date of REC Opinion

    1 Jun 2020

  • REC opinion

    Further Information Favourable Opinion